No Data
No Data
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics | 10-Q: Q3 2024 Earnings Report
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $26
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat's Potential in Hypertension Treatment
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)
No Data
No Data